Bolik K, Hellmann J, Maschauer S, Neu E, Einsiedel J, Riss P
EJNMMI Res. 2024; 14(1):80.
PMID: 39231867
PMC: 11374953.
DOI: 10.1186/s13550-024-01141-2.
Zwart T, Metscher E, van der Boog P, Swen J, De Fijter J, Guchelaar H
Br J Clin Pharmacol. 2022; 88(11):4854-4869.
PMID: 35670960
PMC: 9796409.
DOI: 10.1111/bcp.15433.
Mochizuki T, Aoki Y, Yoshikado T, Yoshida K, Lai Y, Hirabayashi H
Clin Transl Sci. 2022; 15(6):1519-1531.
PMID: 35421902
PMC: 9199885.
DOI: 10.1111/cts.13272.
Uchida M, Hanada N, Yamazaki S, Takatsuka H, Imai C, Utsumi A
J Pharm Health Care Sci. 2022; 8(1):4.
PMID: 35101135
PMC: 8805225.
DOI: 10.1186/s40780-021-00235-6.
Job K, Roberts J, Enioutina E, Illamola S, Kumar S, Rashid J
Expert Opin Drug Metab Toxicol. 2021; 17(7):747-765.
PMID: 34121566
PMC: 10726690.
DOI: 10.1080/17425255.2021.1943356.
Comparing Predictions of a PBPK Model for Cyclosporine With Drug Levels From Therapeutic Drug Monitoring.
Zapke S, Willmann S, Grebe S, Menke K, Thurmann P, Schmiedl S
Front Pharmacol. 2021; 12:630904.
PMID: 34054518
PMC: 8161189.
DOI: 10.3389/fphar.2021.630904.
Analytical performance evaluation of the Elecsys® Cyclosporine and Elecsys® Tacrolimus assays on the cobas e411 analyzer.
Sasano M, Kimura S, Maeda I, Hidaka Y
Pract Lab Med. 2017; 8:10-17.
PMID: 28856221
PMC: 5575412.
DOI: 10.1016/j.plabm.2017.03.001.
PharmGKB summary: cyclosporine and tacrolimus pathways.
Barbarino J, Staatz C, Venkataramanan R, Klein T, Altman R
Pharmacogenet Genomics. 2013; 23(10):563-85.
PMID: 23922006
PMC: 4119065.
DOI: 10.1097/FPC.0b013e328364db84.
Calcineurin inhibitors affect B cell antibody responses indirectly by interfering with T cell help.
Heidt S, Roelen D, Eijsink C, Eikmans M, van Kooten C, Claas F
Clin Exp Immunol. 2009; 159(2):199-207.
PMID: 19922499
PMC: 2810388.
DOI: 10.1111/j.1365-2249.2009.04051.x.
Influence of overt diabetes mellitus on cyclosporine pharmacokinetics in a canine model.
Alkharfy K
Exp Diabetes Res. 2009; 2009:363787.
PMID: 19859566
PMC: 2764377.
DOI: 10.1155/2009/363787.
Blood and plasma pharmacokinetics of ciclosporin in diabetic kidney transplant recipients.
Mendonza A, Gohh R, Akhlaghi F
Clin Pharmacokinet. 2008; 47(11):733-42.
PMID: 18840028
DOI: 10.2165/00003088-200847110-00004.
Changes in serum lipids, independent of weight, are associated with changes in symptoms during long-term clozapine treatment.
Procyshyn R, Wasan K, Thornton A, Barr A, Chen E, Pomarol-Clotet E
J Psychiatry Neurosci. 2007; 32(5):331-8.
PMID: 17823649
PMC: 1963353.
Fenofibrate: a novel formulation (Triglide) in the treatment of lipid disorders: a review.
Tziomalos K, Athyros V
Int J Nanomedicine. 2007; 1(2):129-47.
PMID: 17722529
PMC: 2426786.
DOI: 10.2147/nano.2006.1.2.129.
Influence of dyslipidemia on moxidectin distribution in plasma lipoproteins and on its pharmacokinetics.
Bassissi M, Alvinerie M, Martin P, Perret B, Lespine A
Pharm Res. 2006; 23(11):2672-80.
PMID: 16977498
DOI: 10.1007/s11095-006-9114-2.
Distribution of brevetoxin (PbTx-3) in mouse plasma: association with high-density lipoproteins.
Woofter R, Spiess P, Ramsdell J
Environ Health Perspect. 2005; 113(11):1491-6.
PMID: 16263501
PMC: 1310908.
DOI: 10.1289/ehp.8010.
Compound profiling for P-glycoprotein at the blood-brain barrier using a microplate screening system.
Bauer B, Miller D, Fricker G
Pharm Res. 2003; 20(8):1170-6.
PMID: 12948014
DOI: 10.1023/a:1025040712857.
Association of the endotoxin antagonist E5564 with high-density lipoproteins in vitro: dependence on low-density and triglyceride-rich lipoprotein concentrations.
Wasan K, Sivak O, Cote R, MacInnes A, Boulanger K, Lynn M
Antimicrob Agents Chemother. 2003; 47(9):2796-803.
PMID: 12936976
PMC: 182633.
DOI: 10.1128/AAC.47.9.2796-2803.2003.
Micronised fenofibrate: an updated review of its clinical efficacy in the management of dyslipidaemia.
Keating G, Ormrod D
Drugs. 2002; 62(13):1909-44.
PMID: 12215067
DOI: 10.2165/00003495-200262130-00013.
Distribution of cyclosporin in organ transplant recipients.
Akhlaghi F, Trull A
Clin Pharmacokinet. 2002; 41(9):615-37.
PMID: 12126456
DOI: 10.2165/00003088-200241090-00001.
Rat and rabbit plasma distribution of free and chylomicron-associated BIRT 377, a novel small molecule antagonist of LFA-1-mediated cell adhesion.
Wasan K, Ramaswamy M, Holtorf L, Jayaraj A, Hauss D
Pharm Res. 2001; 18(4):510-9.
PMID: 11451039
DOI: 10.1023/a:1011062512712.